Michael Wyzga, the former chief executive of Radius Health Inc, is set to join the supervisory board of Prosensa Holding NV in the Netherlands which is developing RNA-modulating therapeutics for the treatment of genetic disorders. Mr Wyzga has management experience with rare disease franchises having previously been executive vice president and chief financial officer of Genzyme Corporation until that company’s acquisition by Sanofi SA in 2011. Mr Wyzga currently serves on the boards of directors of OncoMed Pharmaceuticals Inc, Akebia Therapeutics Inc, and Idenix Pharmaceuticals Inc. His appointment at Prosensa is expected to be confirmed in June.
Prosensa announced the appointment on 8 April 2014.
Copyright 2014 Evernow Publishing Ltd